Percutaneous Peritoneal Dialysis Catheter Insertion (PREDICT)

End-stage Kidney Disease Clinical Trial

— PREDICT  

Official title:

Prospective Observational Cohort Study on the Outcomes of Percutaneous Inserted PD Catheters

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06065982
• Other study ID #: UZB-NEF-2023-PREDICT
• Status: Recruiting
• Start date: June 23, 2023
• Est. completion date: June 23, 2027

Study information

• Verified date: March 2023
• Source: Universitair Ziekenhuis Brussel
• Contact: Karlien François, MD PhD
• Phone: +324776055
• Email: Karlien.Francois[@]uzbrussel.be
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Peritoneal dialysis (PD) is the most frequent modality of home dialysis for patients with kidney failure.

Most PD catheters are placed using a laparoscopic technique. This approach requires the availability of a qualified surgeon, time in the operating theater and general anaesthesia for the patient. Thus, the laparoscopic technique is less suitable for patients with severe heart failure or multimorbidity where general anaesthesia is not possible.

PD catheters can also be inserted using a percutaneous strategy using a modified Seldinger technique. This strategy can be performed bedside under local anaesthesia, by the nephrologist, radiologist, a surgeon, physician assistant or qualified nurse.

The availability of the percutaneous implantation strategy of a PD catheter in a nephrology center may accomodate more patients to receive a PD catheter insertion, including those who have a contraindication to general anaesthesia or need urgent PD.

The PREDICT project aims to increase knowledge and competencies on percutaneous PD catheter insertions by training centers for this technique. By establisching a prospective registry, the outcomes of percutaneously inserted PD catheters, both in experienced and newly trained centers, will be assessed.

Description:

The population of the PREDICT study are adult patients requiring a peritoneal dialysis catheter insertion. Decision for percutaneous strategy of catheter insertion (versus surgical catheter insertion) is made by the treating physician.

The inclusion criteria for the prospective PREDICT registry are age > 18 years and percutaneous PD catheter insertion between 1 March 2023 and 1 March 1 2026 in participating centers.

Patients can be included 4 weeks before until 12 weeks after PD catheter insertion. The exclusion criteria are the inability to give informed consent and a life expectancy of less than 3 months.

Demographic and clinical data will be collected for all included patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: June 23, 2027
• Est. primary completion date: June 23, 2026
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• Percutaneous PD catheter insertion between March 1st 2023 and March 1st 2026 Patients can be included 4 weeks before until 12 weeks after PD catheter insertion

Exclusion Criteria:

• Inability to provide informed consent

• Life expectancy < 3 months

Related Conditions & MeSH terms

• End-stage Kidney Disease
• Kidney Diseases
• Kidney Failure, Chronic

Intervention

Other:
• Questionnaires
Health-related quality of life will be measured using the 12-item Short Form (SF-12) and EQ5D-5L questionnaires. The SF-12 is summarized into two component scores, the Physical Component Score (PCS) and Mental Composite Score (MCS).

Locations

Country	Name	City	State
Belgium	Universitair Ziekenhuis Brussel	Brussels
Netherlands	UMC Utrecht	Utrecht

Sponsors (20)

Lead Sponsor

Collaborator

Universitair Ziekenhuis Brussel

Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), az Glorieux, Bernhoven Hospital, Bravis Hospital, Centre Hospitalier Régional de la Citadelle, Centro Hospitalar Universitario do Algarve, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Deventer Ziekenhuis, Erasme University Hospital, HagaZiekenhuis, Imelda Hospital, Bonheiden, Isala, Leiden University Medical Center, Medisch Centrum Leeuwarden, OLVG, Rijnstate Hospital, UMC Utrecht, University Hospital, Antwerp, University Medical Centre Ljubljana

Countries where clinical trial is conducted

Belgium,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Implementation of percutaneus PD catheter insertion technique in dialysis centers	The first co-primary outcome measure assesses the implementation of the percutaneous PD catheter insertion technique in additional dialysis centers.	through study completion, 3 years
Primary	Outcomes of percutaneous inserted PD catheters in participating centers	The second co-primary outcome measure assesses the outcomes of percutaneous inserted PD catheters in participating centers: functionality of PD catheters, defined as catheters usable for PD, over 12 months after percutaneous insertion, and taking into account competing events.	Over 12 months after percutaneous insertion
Secondary	The presence of functioning PD catheter	This secondary outcome measure assesses the presence of functioning PD catheter, defined as catheters usable for PD, over 3 and 6 months after percutaneous PD catheter insertion, censored for competing events.	Over 3 and 6 months after percutaneous PD catheter insertion
Secondary	Insertion-related complications	This secondary outcome measure assesses insertion-related complications, defined as perforation during or within 48 hours after catheter insertion, bleeding within 7 days of insertion and necessitating blood transfusion and/or invasive intervention to control bleeding, and PD-related infections (i.e. exit-site infection, tunnel infection, peritonitis) within 30 days of insertion.	Perforation during or within 48 hours after catheter insertion, bleeding within 7 days of insertion, and PD-related infections within 30 days of insertion
Secondary	Mechanical complications	This secondary outcome measure assesses mechanical complications over 3, 6, and 12 months after percutaneous PD catheter insertion. Relevant mechanical complications are defined as flow restrictions, pericatheter leakage, and abdominal pain resulting in an adverse event that is either a lack of PD start, a delay in PD start, an interruption of PD, a permanent termination of PD, emergency room visits, hospital admissions, or need for invasive procedures related to the mechanical catheter complication.	through study completion of the subject, at 1 year or censored for death or kidney replacement modality switch
Secondary	The rate of PD utilization	This secondary outcome measure assesses the rate of PD utilization, defined as 4 consecutive weeks of PD, after percutaneous PD catheter insertion, censored for competing events.	through study completion of the subject, at 1 year or censored for death or kidney replacement modality switch
Secondary	Health-related quality of life as assessed by the SF-12 questionnaire	This secondary outcome is assesses health-related quality of life using patient-reported outcome measures (PROMs) at baseline and at 12 months after percutaneous PD catheter insertion, using the validated SF-12 questionnaire.	At baseline and at 12 months after percutaneous PD catheter insertion
Secondary	Self-assessed health-related quality of life using the EQ5D questionnaire.	This secondary outcome is assesses health-related quality of life in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using the validated EQ5D questionnaire.	At baseline and at 12 months after percutaneous PD catheter insertion
Secondary	Health care professionals' perspective on the implementation process	This secondary outcome assesses the health care professionals' perspective on the implementation process using the structured Measurement Instrument for Determinants of Innovations. This assessment allows to identify barriers and facilitators of implementation at the level of the percutaneous catheter insertion procedure, at the level of the operator and at the level of the organisation, i.e. the hospital.	At baseline and yearly
Secondary	Evolution in HD/PD ratio in participating centers throughout the study period	This secondary outcome assesses the evolution in HD/PD ratio in participating centers throughout the study period.	Through study completion, 3 years
Secondary	Costs of the procedure	The secondary outcome assesses the costs of the procedure.	immediately after the intervention